Follow The Leader: Bristol Aims To Build On Head Start In Cancer Immunotherapy
Executive Summary
The potential for cancer immunotherapy was the clear takeaway from ASCO 2013. With a lead on the competition, a portfolio with a variety of intriguing mechanisms and many combination trials ongoing, Bristol looks to take immuno-oncology development to the next level.
You may also be interested in...
Bristol’s Oncology Strategy: Stay In The Lead On Immunotherapy
At the recent ASCO meeting, Bristol’s immunotherapies had a very high profile, paving the way for further development of the company’s PD-1/CTLA-4 combination and development of checkpoint inhibitors in new tumor types.
ASCO Preview: Elotuzumab’s ‘Double Whammy’ Mechanism Hits Hard In Myeloma
Lead investigator for Bristol/AbbVie’s Phase III ELOQUENT trial of elotuzumab in myeloma says PFS curves are reminiscent of PD-1 inhibitors, expects overall survival benefit to be evident soon.
Big Market, Broad Plan: Bristol Shares Vision For Opdivo In Lung Cancer
Releasing positive results for Opdivo in the Phase II CheckMate-063 study in highly refractory squamous-type NSCLC, Bristol explains its big tent development program, which tests the PD-1 inhibitor with immunotherapies as well as targeted drugs.